In a research report released yesterday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on shares of TG Therapeutics Inc (NASDAQ:TGTX) with a price target of $33, after the company announced that it reached agreement with the FDA on the Special Protocol Assessment (SPA) of the planned Phase 3 clinical trial combining TG-1101 and TGR-1202 (termed TG-1303) in newly diagnosed and previously treated CLL patients.
Pantginis observed, “Not only is the SPA agreement a promising signal from FDA as to the validity of study design, but we believe the potential to have two experimental drugs approved with a single study (in a combination setting) showcases TGTX’s successful strategy to bring its clinical assets to market. Additionally, enrolling newly diagnosed and previously treated patients also signals management’s belief in being able to reach first-line and second-line settings at once.”
“We believe data from the previous combination study are impressive though they do not yet have PFS data. Recall that ORR with the 1303 combination was 83% in CLL/SLL, 43% in DLBCL, 64% in FL/MZL and 64% across all indications. As we wait for more clarity regarding study design including the dosing regimen and enrollment criteria, we look forward to additional study initiations including 1303+anti-PD-1 and IRAK4 studies, expected to start by YE15,” the analyst added
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of 1.3% and a 43.0% success rate. Pantginis has a 16.5% average return when recommending TGTX, and is ranked #1432 out of 3771 analysts.
All the 4 analysts polled by TipRanks rate TG Therapeutics stock a Buy. With a return potential of 93%, the stock’s consensus target price stands at $26.25.